To the full analysis
Mankind Pharma stock: growth
MANKIND.NSMankind Pharma reported $1.52B in revenue for fiscal 2026, up 17% on the prior year, up 18.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
16.2%
per year from 2019 to 2026, per share 15.7%
Earnings (Annual rate)
18.6%
per year from 2019 to 2026, per share 18.1%
Free cash flow (Annual rate)
29.9%
per year from 2019 to 2026, per share 29.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2019 | |
|---|---|---|
| Revenue | 18.1% | 16.2% |
| Revenue per share | 17.4% | 15.7% |
| Earnings | 8.6% | 18.6% |
| Earnings per share | 8.0% | 18.1% |
| Free cash flow | 18.0% | 29.9% |
| Free cash flow per share | 17.3% | 29.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $529.31M | $61.49M | $32.17M |
| 2020 | $623.41M | $109.52M | $89.47M |
| 2021 | $660.52M | $134.5M | $87.68M |
| 2022 | $827.09M | $152.36M | −$151.54M |
| 2023 | $929.96M | $136.25M | $101.24M |
| 2024 | $1.09B | $203.32M | $188.14M |
| 2025 | $1.3B | $211.62M | $207.54M |
| 2026 | $1.52B | $203.32M | $200.86M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Sep 2025)
- Valuation signal Overvalued since 9 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.